Evidera
Gabriel Chun-Chen Yeh is a data analyst with extensive experience in healthcare and clinical research. Currently serving as Data Analyst II at Evidera, responsibilities include Clinical Outcome Assessment (COA) and Patient-reported outcome (PRO). Prior positions include Statistical Programmer I at Athenex, where Gabriel developed and maintained SAS programs for clinical datasets and collaborated on clinical study reports. Previous roles involved operational analysis at Taipei Medical University Shuangho Hospital, conducting service quality research at Zhongzhang Veterans Home, and supporting international workshops at Taiwan ICDF. Gabriel holds a Master's Degree in Health Services Administration from China Medical University, complemented by a Graduate Summer Session in Epidemiology at the University of Michigan and a Bachelor's Degree in Healthcare Administration from I-Shou University.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.